• Something wrong with this record ?

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic

O. Šušol, B. Šušolová, O. Klempíř, M. Navrátil, J. Gumulec, Z. Kořístek, J. Ďuraš, M. Kaščák, J. Mihályová, L. Stejskal, T. Jelínek, P. Richterová, L. Szeligová, H. Plonková, J. Zuchnická, B. Dluhošová, I. Demel, D. Buffa, K. Hradská, T. Popková,...

. 2024 ; 13 (24) : e70503. [pub] -

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25003122

AIMS: To evaluate antibody response to mRNA vaccine, identify subgroups with poor response and to determine long-term antibody durability in hematological patients. MATERIALS AND METHODS: We have vaccinated 292 patients with all hematological malignancies with a third dose of mRNA COMIRNATY vaccine with a 12-month follow-up period in our center in Ostrava, Czech Republic. RESULTS: Antibody response for the whole cohort exceeded 74% through the whole 12-month follow-up. Lowest seroconversion was observed in CLL cohort (20/41, 48.8%), patients who received anti-CD20 therapy < 6 months before vaccination (8/30, 26.7%) and BTK inhibitors (3/6, 50.0%). On the contrary, patients with chronic myeloproliferative neoplasms and acute leukemia performed comparably with healthy population (33/33; 100% and 12/13; 92.3%, respectively). We have seen better results if the time interval between anti-CD20 therapy and additional vaccine dose was longer than 6 months (5/8 patients achieved seroconversion on 4th booster dose after previous failure). Also, 36 patients received a 4th dose of vaccine as a booster with measurable increase in protective antibodies in 50% (18/36). CONCLUSIONS: Additional doses show promise for a well-timed revaccination even in poor responders. To our knowledge, no study comparable to our work in terms of follow-up length, vaccine consistency or variety of hematological malignancies and/or treatment has been reported yet. Our findings shed more light on long-term antibody response to mRNA vaccines against SARS-CoV-2 in patients with hematological cancer and bring important data for the evaluation of possible vaccine failure and scheduling of subsequent doses.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003122
003      
CZ-PrNML
005      
20250408135155.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.70503 $2 doi
035    __
$a (PubMed)39711119
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Šušol, Ondrej $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000178205987
245    10
$a One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic / $c O. Šušol, B. Šušolová, O. Klempíř, M. Navrátil, J. Gumulec, Z. Kořístek, J. Ďuraš, M. Kaščák, J. Mihályová, L. Stejskal, T. Jelínek, P. Richterová, L. Szeligová, H. Plonková, J. Zuchnická, B. Dluhošová, I. Demel, D. Buffa, K. Hradská, T. Popková, L. Muroňová, M. Lachnit, K. Lančová, R. Hájek
520    9_
$a AIMS: To evaluate antibody response to mRNA vaccine, identify subgroups with poor response and to determine long-term antibody durability in hematological patients. MATERIALS AND METHODS: We have vaccinated 292 patients with all hematological malignancies with a third dose of mRNA COMIRNATY vaccine with a 12-month follow-up period in our center in Ostrava, Czech Republic. RESULTS: Antibody response for the whole cohort exceeded 74% through the whole 12-month follow-up. Lowest seroconversion was observed in CLL cohort (20/41, 48.8%), patients who received anti-CD20 therapy < 6 months before vaccination (8/30, 26.7%) and BTK inhibitors (3/6, 50.0%). On the contrary, patients with chronic myeloproliferative neoplasms and acute leukemia performed comparably with healthy population (33/33; 100% and 12/13; 92.3%, respectively). We have seen better results if the time interval between anti-CD20 therapy and additional vaccine dose was longer than 6 months (5/8 patients achieved seroconversion on 4th booster dose after previous failure). Also, 36 patients received a 4th dose of vaccine as a booster with measurable increase in protective antibodies in 50% (18/36). CONCLUSIONS: Additional doses show promise for a well-timed revaccination even in poor responders. To our knowledge, no study comparable to our work in terms of follow-up length, vaccine consistency or variety of hematological malignancies and/or treatment has been reported yet. Our findings shed more light on long-term antibody response to mRNA vaccines against SARS-CoV-2 in patients with hematological cancer and bring important data for the evaluation of possible vaccine failure and scheduling of subsequent doses.
650    _2
$a lidé $7 D006801
650    12
$a hematologické nádory $x imunologie $x terapie $7 D019337
650    _2
$a mužské pohlaví $7 D008297
650    12
$a COVID-19 $x prevence a kontrola $x imunologie $7 D000086382
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a sekundární imunizace $7 D007117
650    _2
$a dospělí $7 D000328
650    12
$a SARS-CoV-2 $x imunologie $7 D000086402
650    12
$a vakcíny proti COVID-19 $x imunologie $x aplikace a dávkování $7 D000086663
650    12
$a protilátky virové $x krev $x imunologie $7 D000914
650    _2
$a mRNA vakcíny $7 D000087503
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a časové faktory $7 D013997
650    _2
$a následné studie $7 D005500
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Šušolová, Barbora $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Klempíř, Ondřej $u Department of Biomedical Informatics, Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic
700    1_
$a Navrátil, Milan $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Gumulec, Jaromír $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Kořístek, Zdeněk $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Ďuraš, Juraj $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Kaščák, Michal $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Mihályová, Jana $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Stejskal, Lukáš $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Haematology and Blood Transfusion, Silesian Hospital in Opava, Opava, Czech Republic
700    1_
$a Jelínek, Tomáš $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Richterová, Petra $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Szeligová, Lenka $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Plonková, Hana $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Zuchnická, Jana $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Dluhošová, Barbora $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Demel, Ivo $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000205189581 $7 xx0268008
700    1_
$a Buffa, David $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Hradská, Katarína $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Popková, Tereza $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000158854218
700    1_
$a Muroňová, Ludmila $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0009000385891577
700    1_
$a Lachnit, Martin $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $7 xx0330938
700    1_
$a Lančová, Klára $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Hájek, Roman $u Department of Haemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 13, č. 24 (2024), s. e70503
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39711119 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250408135152 $b ABA008
999    __
$a ok $b bmc $g 2263088 $s 1239129
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 13 $c 24 $d e70503 $e - $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options